• Explore /
  • Poster
  • / Intravesical recombinant BCG followed by perioperative chemo-immunotherapy for patients with muscle-invasive bladder cancer (MIBC): A multicenter, single arm phase 2 trial (SAKK 06/19).

Intravesical recombinant BCG followed by perioperative chemo-immunotherapy for patients with muscle-invasive bladder cancer (MIBC): A multicenter, single arm phase 2 trial (SAKK 06/19).

Abstract Poster

Authors

null

Richard Cathomas

Division of Oncology, Cantonal Hospital Graubunden, Chur, Switzerland

Richard Cathomas , Martin Spahn , Stefanie Hayoz , Sabrina Chiquet , Martina Schneider , Cyrill A. Rentsch , Sacha Rothschild , Ulf Petrausch

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Genitourinary Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session B: Urothelial Carcinoma

Track

Urothelial Carcinoma

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT04630730

Citation

J Clin Oncol 42, 2024 (suppl 4; abstr TPS707)

DOI

10.1200/JCO.2024.42.4_suppl.TPS707

Abstract #

TPS707

Poster Bd #

M7

Abstract Disclosures

Similar Posters

First Author: Ali Raza Khaki

First Author: John J Coen

Poster

2024 ASCO Genitourinary Cancers Symposium

Preliminary efficacy and safety results from ReBirth: A phase II study of risk-based bladder-sparing therapy for MIBC.

Preliminary efficacy and safety results from ReBirth: A phase II study of risk-based bladder-sparing therapy for MIBC.

First Author: Yijun Shen

First Author: Xiao Yang